Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Osteoporosis
Interventions
DRUG

Teriparatide

Daily for 96 days

Trial Locations (10)

Unknown

Osteocentrum FN, Hradec Králové

Osteocentrum 3 .Interni Klinika 1. LFUK a VFN, Prague

Drug Research Center, Balatonfüred

Semmelweis University Department of Orthopedic, Budapest

Kenezy Gyula Hospital Department of Rheumatology, Debrecen

Szent Andras Hospital-Heviz, Hévíz

Szent Ferenc Hospital Department of Rheumatology, Miskolc

Hillel Yafe Medical Center - Endocrinology dep, Hadera

Rambam Medical Center, Haifa

Hadassah Medical Center Osteoporosis Center, Jerusalem

Sponsors
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

TransPharma Medical

INDUSTRY

NCT00535860 - Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter